Heart failure & cardiomyopathiesSecondary analysis
Frailty Status Modifies the Efficacy of Implantable Cardioverter-defibrillator (ICD) Therapy for Primary Prevention Among Patients With HF
- Secondary analysis of the SCD-HeFT randomised trial
Authors' conclusion
Baseline frailty modified the efficacy of ICD therapy with a significant mortality benefit observed among participants with HFrEF and a low frailty burden but not among those with a high frailty burden.
Study context
- Population
- Patients with heart failure with reduced ejection fraction (HFrEF) in SCD-HeFT, stratified by Rockwood Frailty Index (high: Frailty Index (FI) > median; low: FI ≤ median)
- Participants
- 1,676 patients
- Comparison
- ICD vs placebo, by baseline frailty
- Primary endpoint
- All-cause mortality (effect modification of ICD efficacy by baseline frailty)
Primary result
As reported in the abstract
All-cause mortality, by frailty burden (subgroups)
ICD vs PlaceboHazard ratio (95% CI)
low frailty burden
0.56(0.40–0.78)
high frailty burden
0.86(0.68–1.09)
Original publication
Frailty Status Modifies the Efficacy of ICD Therapy for Primary Prevention Among Patients With HF. JACC Heart Fail. Published 9 August 2023. doi:10.1016/j.jchf.2023.06.009
Summarised from the published abstract; every number is checked against it